Kyle Munz

An observational registry study revealed that inflammatory disease activity is not the only factor influencing the achievement of treatment targets for patients with rheumatoid arthritis (RA).

A retrospective, single-center study out of the Czech Republic tested the safety and efficacy of unilateral interlaminar fenestration (UILF) on the convex side in cases of SMA that also exhibit severe spinal deformities.

A single-center, observational study conducted in the Czech Republic investigated the determining factors in delayed diagnoses in multiple sclerosis (MS) and how these delays impact patient outcomes.

This year’s most-read articles on inflammation explored predictive biomarkers, medication acceptance, the impacts of long COVID-19, and more.

Following the FDA approval of vonoprazan in the treatment of erosive esophagitis, Dr Colin Howden discussed important information about the new therapy.

This year’s most-read spinal muscular atrophy(SMA) articles explored mental health, new technologies, caregiver well-being, and more.

This year’s most-read articles on autoimmune diseases explored comorbidities with cardiovascular disease, the value of new forms of monitoring and therapy, and more.

Colin Howden, MD, discusses the mechanisms at work in vonoprazan as well as patient monitoring and potential future uses following a recent FDA approval for the treatment of erosive esophagitis.

This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS.

Ana Ferrigno Guajardo, MD, discusses lingering questions following the results of a study on taxane chemotherapy interventions in patients with breast cancer during pregnancy.

Siddhartha Yadav, MD, discusses real-world data demonstrating the mass underutilization of BRCA testing in patients with breast cancer.

For the first time, researchers identified sex-based differences in genetic expression of human pulmonary microvascular endothelial cells (HPMECs).

Gabriel Hortobagyi, MD, FACP, talks about the potential for further studies in HR-positive/HER2-negative breast cancer following the results of the NATALEE trial.

Stephanie Graff, MD, details insights from a study evaluating the perspectives and perceptions on clinical meaningfulness from patients, clinicians, and caregivers.

Kelly-Anne Phillips, MD, shares new findings suggesting that hormonal contraceptive use can increase the risk for breast cancer in those with genetic variants of BRCA1 and BRCA2.

Sara Hurvitz, MD, FACP, shares insights into the results of the HER2CLIMB-02 trial, which saw patients with HER2-positive breast cancer benefit from the addition of tucatinib to trastuzumab emtansine (T-DM1).

A non-randomized, open-label, single-site clinical trial evaluated the safety and pharmacokinetics of acetaminophen intake in adults and children with spinal muscular atrophy (SMA) type II.

Virginia Kaklamani, MD, previews sessions of interest and overviews what to look forward to heading into the San Antonio Breast Cancer Symposium (SABCS) 2023.

A case report highlights the benefits of applying patient-tailored therapies to mitigate the effects of neuromuscular immune-related adverse events and improve patient outcomes.

A cross-sectional study suggests that spinal muscular atrophy (SMA) can contribute to cognitive impairment.

A cross-sectional study revealed that neuroinflammation is linked to irritability, among other neuropsychiatric symptoms, in patients with Alzheimer disease (AD).

A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.

A network meta-analysis confirmed the efficacy of methotrexate for patients with rheumatoid arthritis (RA) and validated it as the primary reference conventional synthetic disease-modifying antirheumatic drug for treatment in this population.

A retrospective analysis reveals that pregnant patients with autoimmune skin diseases have higher risks for adverse pregnancy outcomes.

In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.

Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.

The recent availability of 3 FDA-approved treatments for patients with spinal muscular atrophy (SMA) has dramatically altered patient outcomes and provided a wealth of new avenues for SMA research.

In a single-center, retrospective analysis, echocardiography demonstrated low sensitivity but high specificity for diagnosing pulmonary hypertension (PH) in advanced chronic obstructive pulmonary disease (COPD).

To stress the importance of considering pulmonary complications in sickle cell disease (SCD), researchers compiled an overview on the state of research and available treatment options for patients with SCD associated with pulmonary hypertension.

Alexander Fay, MD, PhD, joined for a Q&A about the current state of spinal muscular atrophy (SMA) treatment and the unanswered questions in the field.